Science 37 Holdings Past Earnings Performance
Past criteria checks 0/6
Science 37 Holdings's earnings have been declining at an average annual rate of -46.3%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 23.9% per year.
Key information
-46.3%
Earnings growth rate
36.9%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 23.9% |
| Return on equity | -240.9% |
| Net Margin | -206.9% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks
Dec 18
Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)
Apr 17Science 37, Syapse team for faster patient enrollment in cancer trials
Aug 18Science 37 reports Q2 mixed earnings; narrows FY22 guidance
Aug 11Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 13Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans
Apr 11Science 37: Pioneering Decentralized Clinical Trials
Jan 02We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth
Nov 04Revenue & Expenses BreakdownBeta
How Science 37 Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 60 | -125 | 76 | 0 |
| 30 Jun 23 | 62 | -134 | 86 | 0 |
| 31 Mar 23 | 66 | -121 | 97 | 0 |
| 31 Dec 22 | 70 | -51 | 107 | 0 |
| 30 Sep 22 | 75 | -50 | 121 | 0 |
| 30 Jun 22 | 73 | -41 | 113 | 0 |
| 31 Mar 22 | 66 | -43 | 97 | 0 |
| 31 Dec 21 | 60 | -94 | 76 | 0 |
| 30 Sep 21 | 50 | -42 | 54 | 0 |
| 30 Jun 21 | 43 | -35 | 44 | 0 |
| 31 Mar 21 | 33 | -33 | 38 | 0 |
| 31 Dec 20 | 24 | -32 | 34 | 0 |
| 31 Dec 19 | 14 | -18 | 23 | 0 |
Quality Earnings: SNCE is currently unprofitable.
Growing Profit Margin: SNCE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SNCE is unprofitable, and losses have increased over the past 5 years at a rate of 46.3% per year.
Accelerating Growth: Unable to compare SNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNCE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-7.9%).
Return on Equity
High ROE: SNCE has a negative Return on Equity (-240.9%), as it is currently unprofitable.